Golling, Greg

Znomics is employing breakthrough genetic advances with zebrafish to improve and speed human drug discovery. The Znomics discovery platform is based on two key technologies: 1) development of disease models and assays in zebrafish that are suitable for high-throughput in vivo drug discovery and 2) for drug target discovery, a new retroviral insertional mutagenesis system that allows for mutation of all of the 40,000+ zebrafish genes followed by rapid recovery of genes of interest. This tagged mutant gene library ('ZeneMark? Library') will be the first of its kind in any vertebrate. With this set of lesions, company scientists can then identify all genes that contribute to a particular disease-related process.